Utama › Kanser Hipofaring
Kajian klinikal Kanser Hipofaring sedang mengambil peserta di AS
19 kajian untuk Kanser Hipofaring sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Atlanta, GA6 kajian
- Chicago, IL6 kajian
- Stevens Point, WI5 kajian
- Joliet, IL5 kajian
- Peoria, IL5 kajian
- Bloomington, IL5 kajian
- Wausau, WI5 kajian
- Richmond, VA5 kajian
- Cape Girardeau, MO5 kajian
- Milwaukee, WI5 kajian
- Kansas City, MO5 kajian
- New York City, NY4 kajian
- Edison, NJ4 kajian
- Queens, NY4 kajian
- Waukegan, IL4 kajian
- Green Bay, WI4 kajian
- Cedar Rapids, IA4 kajian
- Evanston, IL4 kajian
- Danville, IL4 kajian
- Fargo, ND4 kajian
- Lansing, MI4 kajian
- Omaha, NE4 kajian
- Champaign, IL4 kajian
- Decatur, IL4 kajian
- Aurora, IL4 kajian
- St. Louis, MO4 kajian
- Galesburg, IL4 kajian
- Naperville, IL4 kajian
- Flint, MI4 kajian
- Oklahoma City, OK4 kajian
- Charleston, IL4 kajian
- Cicero, IL4 kajian
- North Peoria, IL4 kajian
- Waterford, MI4 kajian
- Bozeman, MT4 kajian
- Duluth, MN4 kajian
- Pittsburgh, PA4 kajian
- Baltimore, MD4 kajian
- Cincinnati, OH4 kajian
- Louisville, KY4 kajian
Mengikut negeri
- Arizona3 kajian
- Arkansas4 kajian
- California7 kajian
- Colorado6 kajian
- Florida8 kajian
- Georgia6 kajian
- Idaho3 kajian
- Illinois7 kajian
- Indiana4 kajian
- Iowa6 kajian
- Kansas6 kajian
- Kentucky4 kajian
- Maryland5 kajian
- Massachusetts5 kajian
- Michigan5 kajian
- Minnesota6 kajian
- Missouri6 kajian
- Montana4 kajian
- Nebraska4 kajian
- New Jersey4 kajian
- New York8 kajian
- North Carolina5 kajian
- North Dakota4 kajian
- Ohio8 kajian
- Oklahoma4 kajian
- Oregon3 kajian
- Pennsylvania6 kajian
- South Dakota3 kajian
- Texas3 kajian
- Virginia5 kajian
- Wisconsin6 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06589804Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06997068BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT01365169Integrated Cancer Repository for Cancer Research
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mac 2026 · NCT06868433A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Feb 2026 · NCT07063212Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Feb 2026 · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Feb 2026 · NCT01473784Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Okt 2025 · NCT06914999Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Mengambil pesertaKajian pemerhatian
Umur 21 hingga 90 · Semua jantina · Dikemas kini 22 Sep 2025 · NCT00900419Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.